Lymphatic Malformations Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – Vanthera, Protara, Cerecor, Bridge Bio, Palvella, Zynerba

Lymphatic Malformations Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies - Vanthera, Protara, Cerecor, Bridge Bio, Palvella, Zynerba
Delveinsight Business Research LLP
As per DelveInsight assessments, the market size of Lymphatic Malformations (LM) in the 7MM is anticipated to grow immensely in the coming years. Among 7MM, the United States accounted for the highest Lymphatic Malformations (LM) market size compared to EU5 and Japan.

Currently, only a few pipeline products are in clinical development for the treatment of Lymphatic Malformations. Protara Therapeutics, Cerecor, and Venthera are the key players. However, the increasing incidence of Lymphatic Malformations and the launch of emerging therapies during the forecasted period would increase the market size.

DelveInsight’s “Lymphatic Malformations Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Lymphatic Malformations market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Lymphatic Malformations market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Lymphatic Malformations Market

Lymphatic Malformations: An Overview

Lymphatic malformations (LM), also known as Lymphangiomas, are characterized by the overgrowth of lymphatic vessels during pre-and postnatal development. They are congenital malformations of the lymphatic system and consist of channels and cystic spaces of varying size and result in fluid accumulation, often beneath the skin.

Embryologically, they are thought to originate from the sequestration of lymphatic tissue during the development of lymphaticovenous sacs, which then fail to communicate with the remainder of the lymphatic or venous system. Later on, the sequestered lymphatic tissues dilate, which results in the cystic morphology of the lesions.

Based on the size of the lymphatic lumen, Lymphatic Malformations can be divided into microcystic, macrocystic lesions, and combined forms. They are also classified into superficial lesions known as lymphangioma circumscriptum, and more deep-seated lesions.

Lymphatic Malformations Market Key Facts

  • Lymphatic Malformations can affect multiple organs and systems, participating in a vast differential diagnosis depending on their site of involvement. This makes the role of the radiologist in recognition of typical patterns of imaging paramount, allowing a more assertive diagnosis. Treatment of Microcystic LM is a complex matter and is associated with high rates of relapse (50%–66%).

  • The prevalence of lymphangiomas has been estimated to be 1.1–5.3 cases/10,000 live births. However, the prevalence appears to be higher when the studies include live births, terminated pregnancies, and stillbirths: then, the estimate is 30 cases/10,000 in the US (Forrester et al.).

  • Lymphatic malformations can be observed in any anatomic region but are more commonly found in lymphatic-rich areas, such as the head and neck (45–52%), axilla, mediastinum, groin, and retroperitoneum. (Elluru et al., 2014).

  • According to NORD, lymphatic malformations affect males and females in equal numbers. Most lymphatic malformations are evident at birth or within two years of age. However, in some patients, lymphatic malformations may not become apparent until adulthood. The exact prevalence of lymphatic malformations in the general population is unknown but is thought to be approximately 1:4000 live births.

Lymphatic Malformations Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Lymphatic Malformations market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Lymphatic Malformations market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Lymphatic Malformations Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Lymphatic Malformations Epidemiology, Segmented as –

  • Prevalent Cases of Lymphatic malformations in the 7MM (2019–2032)

  • Diagnosed and Treated Cases of Lymphatic malformations (2019–2032)

  • Location-specific Cases of Lymphatic malformations {head, neck, and others} (2019–2032)

Lymphatic Malformations Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Lymphatic Malformations market or expected to be launched during the study period. The analysis covers the Lymphatic Malformations market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Lymphatic Malformations pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Lymphatic Malformations Market Will Evolve and Grow by 2032 @

Lymphatic Malformations Therapeutics Analysis

There are no treatments approved by the US FDA for either macrocystic or microcystic lymphatic malformations. The current standard of care treatment options is mainly limited to procedural interventions such as surgery and sclerotherapy. Treatment success rates for surgery vary, especially for large infiltrative disease, and sclerotherapy, which involves the injection of a sclerosant into the vascular structure, is associated with a higher response rate of up to 75% in macrocystic LM but much less successful in microcystic Lymphatic Malformations.

Several major pharma and biotech companies are developing therapies for Lymphatic Malformations to improve the treatment scenario. Currently, Protara Therapeutics is leading the therapeutics market with its Lymphatic Malformations drug candidates in the most advanced stage of clinical development.

The Leading Companie in the Lymphatic Malformations Therapeutics Market Include:

  • Protara therapeutics

  • Vanthera

  • Cerecor, Inc.

  • Bridge Bio

  • Palvella Therapeutics

  • Zynerba Pharmaceuticals

And Many Others

Lymphatic Malformations Emerging and Marketed Drugs Covered in the Report Include:

  • TARA-002: Protara Therapeutics

  • VT30 – Venthera and Bridge Bio

  • CERC-006: Cerecor

  • PTX022 – Palvella Therapeutics

  • ZYN002 – Zynerba Pharmaceuticals

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Lymphatic Malformations Competitive Intelligence Analysis

4. Lymphatic Malformations Market Overview at a Glance

5. Lymphatic Malformations Disease Background and Overview

6. Lymphatic Malformations Patient Journey

7. Lymphatic Malformations Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Lymphatic Malformations Treatment Algorithm, Current Treatment, and Medical Practices

9. Lymphatic Malformations Unmet Needs

10. Key Endpoints of Lymphatic Malformations Treatment

11. Lymphatic Malformations Marketed Products

12. Lymphatic Malformations Emerging Drugs and Latest Therapeutic Advances

13. Lymphatic Malformations Seven Major Market Analysis

14. Attribute Analysis

15. Lymphatic Malformations Market Outlook (In US, EU5, and Japan)

16. Lymphatic Malformations Access and Reimbursement Overview

17. KOL Views on the Lymphatic Malformations Market

18. Lymphatic Malformations Market Drivers

19. Lymphatic Malformations Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States